XOMA Co. (NASDAQ:XOMAO – Get Free Report) saw a large drop in short interest in April. As of April 30th, there was short interest totaling 290 shares, a drop of 89.8% from the April 15th total of 2,830 shares. Based on an average daily volume of 8,328 shares, the short-interest ratio is currently 0.0 days.
XOMA Stock Up 0.0%
Shares of XOMAO stock traded up $0.01 on Wednesday, hitting $25.24. The company’s stock had a trading volume of 1,328 shares, compared to its average volume of 3,953. XOMA has a fifty-two week low of $24.86 and a fifty-two week high of $26.40. The firm’s fifty day moving average price is $25.48 and its 200-day moving average price is $25.43.
XOMA Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Thursday, April 2nd were given a dividend of $0.5234 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.09 dividend on an annualized basis and a yield of 8.3%.
About XOMA
XOMA Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies. The company applies its proprietary protein engineering and antibody optimization platform to generate novel drug candidates targeting autoimmune, inflammatory and metabolic diseases. XOMA’s scientific expertise spans antibody discovery, engineering, in vitro and in vivo testing, and early‐stage clinical development.
In addition to advancing its own pipeline of antibody candidates, XOMA collaborates with pharmaceutical and biotechnology partners to provide research and development services.
See Also
- Five stocks we like better than XOMA
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
- 3 Sectors That Look Most Vulnerable Ahead of May 15
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
